Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer

KRAS mutations are associated with tumor resistance to EGFR TKIs (erlotinib, gefitinib) and to monoclonal antibody against EGFR (cetuximab). Targeted treatment of mutated RAS patients is still considered as a challenge. Inhibitors of c-Met (onartuzumab or tiwantinib) and MEK (selumetinib—a dual inhi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Exp Med
Egile Nagusiak: Nicoś, Marcin, Krawczyk, Paweł, Jarosz, Bożena, Sawicki, Marek, Szumiłło, Justyna, Trojanowski, Tomasz, Milanowski, Janusz
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer International Publishing 2015
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4844634/
https://ncbi.nlm.nih.gov/pubmed/25902737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10238-015-0349-2
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak